<DOC>
	<DOCNO>NCT00502736</DOCNO>
	<brief_summary>This single arm study ass efficacy safety load dos intravenous Bondronat patient breast cancer malignant bone disease experience moderate severe bone pain . Patients receive intravenous infusion 6mg Bondronat day 1 , 2 3 . The anticipated time study treatment 3 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Loading Doses Intravenous Bondronat ( Ibandronate ) Patients With Breast Cancer Malignant Bone Disease .</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>female patient , &gt; =18 year age ; breast cancer ; bone metastases ; moderate severe pain ; adequate renal function . bisphosphonate treatment within 3 week study enrollment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>